

Switch from ibalizumab to lenacapavir in a salvage therapy for a patient with multidrug-resistant HIV infection

S. Martini1, N. Cuomo2, A. Russo1, R. Palladino1, A. Raddi2, M. Pisaturo1, N. Coppola1

1UOC Malattie infettive Università degli studi della Campania Luigi Vanvitelli

2AORN dei COLLI, Unità di Malattie Infettive ospedale Cotugno, Napoli

Introduction

Results


Advances in antiretroviral therapy have improved efficacy, but some patients show multidrug resistances(MDR)¹.The guidelines in this case suggest using new generation drugs together to those with residual efficacy. Ibalizumab is a new monoclonal antibody that blocks the CD4 cell receptor. Lenacapavir is a new viral capsid inhibitor, which represents a new therapeutic target.

Study Design

Our clinical case concerns a patient with MDR HIV infection. A salvage therapy was therefore set up combining drugs not completely effective (etravirine + tenofovir/emtricitabine + dolutegravir) with Ibalizumab.

Methods

At the time of introduction of this regimen, HIV-RNA resulted 37,800 CD4+ copies/ml and were 147 cells/µL (14%). Ibalizumab is administered intravenously and was in April 2022, as started first monotherapy with a loading dose of 2000 mg, then after 7 days an 800 mg dose associated with residual effective drugs. Subsequently, this dose was repeated every 15 days.



This salvage therapy showed viro-immunological efficacy. After 7 days, ibalizumab alone had already reduced the HIV viral load by 2 logs. Then, after association with other drugs that are still partially effective, viral suppression was achieved in only one month. The CD4 count improved from 147(14%)to 230 cells/µL(19.3%).There were no adverse events except hypertension after ibalizumab infusions. During the follow-up we also noticed a progressive reduction in the detectability of viral mutations in the reservoir. HIV-DNA genotyping test in fact no longer showed viral mutations that were evident before this salvage regimen. After 6 months of treatment, the patient voluntarily discontinued ibalizumab. without losina viro-immunological efficacy, however we modified the therapeutic regimen from ibalizumab switching to lenacapavir. This drug had a more favorable long-acting dosage, being administered subcutaneously every 6 months. The new drug showed good efficacy and tolerability. After 6 months of treatment, viro-immunological efficacy was maintained with CD4+ 259(20,2%),HIV-RNA undetectable and stable pressure on HIV-DNA in terms of reduced detectability of initial viral





Fig. 1, 2 and 3 HIV Drug Resistance Mutations

Results of 2






Fig. 4 and 5 Viro-immunological efficacy

Conclusion

Our case report shows that ibalizumab was effective in a salvage regimen, obtaining virological suppression and an immunological recovery, never previously reached by the patient. The efficacy was also highlighted in the reservoir with a progressive reduction of HIV-DNA demonstrated by the impossibility of detecting initial previous mutations. The overall safety profile was good, despite hypertension following ibalizumab infusions. The subsequent switch to maintained lenacapavir the viro-immunological efficacy and stable pressure on HIV-DNA, showing good tolerability and better posology, being administered by subcutaneous injection, once every 6 months. This case report shows efficacy of lenacapavir in switch strategy in a salvage regimen, in a context in which there are no data in the literature.

Reference

1. Hannah A Blair. Ibalizumab: A Review in Multidrug-Resistant HIV-1 Infection. Drugs 2020 Feb;80(2):189-196. doi:10.1007/s40265-020-01258-3.